Cargando…
Qualitative factors shaping MS patients’ experiences of infusible disease-modifying drugs: a critical incident technique analysis
OBJECTIVE: To explore factors shaping the experiences of patients with relapsing-remitting multiple sclerosis with infusible disease-modifying drugs in a hospital setting. DESIGN AND SETTINGS: The critical incident technique served as a framework for collecting and analysing patients’ qualitative ac...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443265/ https://www.ncbi.nlm.nih.gov/pubmed/32819993 http://dx.doi.org/10.1136/bmjopen-2020-037701 |
_version_ | 1783573599820447744 |
---|---|
author | Larsen, Janni Lisander Schäfer, Jakob Nielsen, Helle Hvilsted Vestergaard Rasmussen, Peter |
author_facet | Larsen, Janni Lisander Schäfer, Jakob Nielsen, Helle Hvilsted Vestergaard Rasmussen, Peter |
author_sort | Larsen, Janni Lisander |
collection | PubMed |
description | OBJECTIVE: To explore factors shaping the experiences of patients with relapsing-remitting multiple sclerosis with infusible disease-modifying drugs in a hospital setting. DESIGN AND SETTINGS: The critical incident technique served as a framework for collecting and analysing patients’ qualitative account practices involving infusible disease-modifying drugs. Data were collected through semistructured interviews and one single-case study. Participants were recruited from all five regions in Denmark. Inductive thematic analysis was used to identify and interpret factors shaping patients’ infusion journey over time. PARTICIPANTS: Twenty-two patients with relapsing-remitting multiple sclerosis receiving infusion with disease-modifying drugs (natalizumab, alemtuzumab and ocrelizumab). RESULTS: Four time scenarios—preinfusion, day of infusion, long-term infusion and switch of infusion—associated with the infusion of disease-modifying drugs were analysed to reveal how different factors could both positively and negatively affect patient experience. Time taken to make the treatment decision was affected by participants’ subjective perceptions of their disease activity; this may have set off a treatment dilemma in the event of a pressing need for treatment. Planning and routine made infusion practices manageable, but external and internal surroundings, including infusion room ambience and the quality of relationships with healthcare professionals and fellow patients, affected patients’ cognitive state and well-being irrespective of the infusion regimen. Switching the infusion regimen can reactivate worries akin to the preinfusion scenario. CONCLUSION: This study provides novel insight into the positive and negative factors that shape patients’ experience of infusion care practices. From a patient’s perspective, an infusion practice is not a solitary event in time but includes planning and routine which become an integral part of their multiple sclerosis management. The quality of space and the ambience of the infusion room, combined with the relationship with healthcare professionals and fellow patients, can be a significant source of knowledge and support people with relapsing-remitting multiple sclerosis in their experience of agency in life. |
format | Online Article Text |
id | pubmed-7443265 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-74432652020-08-28 Qualitative factors shaping MS patients’ experiences of infusible disease-modifying drugs: a critical incident technique analysis Larsen, Janni Lisander Schäfer, Jakob Nielsen, Helle Hvilsted Vestergaard Rasmussen, Peter BMJ Open Neurology OBJECTIVE: To explore factors shaping the experiences of patients with relapsing-remitting multiple sclerosis with infusible disease-modifying drugs in a hospital setting. DESIGN AND SETTINGS: The critical incident technique served as a framework for collecting and analysing patients’ qualitative account practices involving infusible disease-modifying drugs. Data were collected through semistructured interviews and one single-case study. Participants were recruited from all five regions in Denmark. Inductive thematic analysis was used to identify and interpret factors shaping patients’ infusion journey over time. PARTICIPANTS: Twenty-two patients with relapsing-remitting multiple sclerosis receiving infusion with disease-modifying drugs (natalizumab, alemtuzumab and ocrelizumab). RESULTS: Four time scenarios—preinfusion, day of infusion, long-term infusion and switch of infusion—associated with the infusion of disease-modifying drugs were analysed to reveal how different factors could both positively and negatively affect patient experience. Time taken to make the treatment decision was affected by participants’ subjective perceptions of their disease activity; this may have set off a treatment dilemma in the event of a pressing need for treatment. Planning and routine made infusion practices manageable, but external and internal surroundings, including infusion room ambience and the quality of relationships with healthcare professionals and fellow patients, affected patients’ cognitive state and well-being irrespective of the infusion regimen. Switching the infusion regimen can reactivate worries akin to the preinfusion scenario. CONCLUSION: This study provides novel insight into the positive and negative factors that shape patients’ experience of infusion care practices. From a patient’s perspective, an infusion practice is not a solitary event in time but includes planning and routine which become an integral part of their multiple sclerosis management. The quality of space and the ambience of the infusion room, combined with the relationship with healthcare professionals and fellow patients, can be a significant source of knowledge and support people with relapsing-remitting multiple sclerosis in their experience of agency in life. BMJ Publishing Group 2020-08-20 /pmc/articles/PMC7443265/ /pubmed/32819993 http://dx.doi.org/10.1136/bmjopen-2020-037701 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Neurology Larsen, Janni Lisander Schäfer, Jakob Nielsen, Helle Hvilsted Vestergaard Rasmussen, Peter Qualitative factors shaping MS patients’ experiences of infusible disease-modifying drugs: a critical incident technique analysis |
title | Qualitative factors shaping MS patients’ experiences of infusible disease-modifying drugs: a critical incident technique analysis |
title_full | Qualitative factors shaping MS patients’ experiences of infusible disease-modifying drugs: a critical incident technique analysis |
title_fullStr | Qualitative factors shaping MS patients’ experiences of infusible disease-modifying drugs: a critical incident technique analysis |
title_full_unstemmed | Qualitative factors shaping MS patients’ experiences of infusible disease-modifying drugs: a critical incident technique analysis |
title_short | Qualitative factors shaping MS patients’ experiences of infusible disease-modifying drugs: a critical incident technique analysis |
title_sort | qualitative factors shaping ms patients’ experiences of infusible disease-modifying drugs: a critical incident technique analysis |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443265/ https://www.ncbi.nlm.nih.gov/pubmed/32819993 http://dx.doi.org/10.1136/bmjopen-2020-037701 |
work_keys_str_mv | AT larsenjannilisander qualitativefactorsshapingmspatientsexperiencesofinfusiblediseasemodifyingdrugsacriticalincidenttechniqueanalysis AT schaferjakob qualitativefactorsshapingmspatientsexperiencesofinfusiblediseasemodifyingdrugsacriticalincidenttechniqueanalysis AT nielsenhellehvilsted qualitativefactorsshapingmspatientsexperiencesofinfusiblediseasemodifyingdrugsacriticalincidenttechniqueanalysis AT vestergaardrasmussenpeter qualitativefactorsshapingmspatientsexperiencesofinfusiblediseasemodifyingdrugsacriticalincidenttechniqueanalysis |